calcimycin has been researched along with vapiprost* in 2 studies
2 other study(ies) available for calcimycin and vapiprost
Article | Year |
---|---|
The cyclo-oxygenase-dependent regulation of rabbit vein contraction: evidence for a prostaglandin E2-mediated relaxation.
1. Arachidonic acid (0.01-1 microM) induced relaxation of precontracted rings of rabbit saphenous vein, which was counteracted by contraction at concentrations higher than 1 microM. Concentrations higher than 1 microM were required to induce dose-dependent contraction of vena cava and thoracic aorta from the same animals. 2. Pretreatment with a TP receptor antagonist (GR32191B or SQ29548, 3 microM) potentiated the relaxant effect in the saphenous vein, revealed a vasorelaxant component in the vena cava response and did not affect the response of the aorta. 3. Removal of the endothelium from the venous rings, caused a 10 fold rightward shift in the concentration-relaxation curves to arachidonic acid. Whether or not the endothelium was present, the arachidonic acid-induced relaxations were prevented by indomethacin (10 microM) pretreatment. 4. In the saphenous vein, PGE2 was respectively a 50 and 100 fold more potent relaxant prostaglandin than PGI2 and PGD2. Pretreatment with the EP4 receptor antagonist, AH23848B, shifted the concentration-relaxation curves of this tissue to arachidonic acid in a dose-dependent manner. 5. In the presence of 1 microM arachidonic acid, venous rings produced 8-10 fold more PGE2 than did aorta whereas 6keto-PGF1alpha and TXB2 productions remained comparable. 6. Intact rings of saphenous vein relaxed in response to A23187. Pretreatment with L-NAME (100 microM) or indomethacin (10 microM) reduced this response by 50% whereas concomitant pretreatment totally suppressed it. After endothelium removal, the remaining relaxing response to A23187 was prevented by indomethacin but not affected by L-NAME. 7. We conclude that stimulation of the cyclo-oxygenase pathway by arachidonic acid induced endothelium-dependent, PGE2/EP4 mediated relaxation of the rabbit saphenous vein. This process might participate in the A23187-induced relaxation of the saphenous vein and account for a relaxing component in the response of the vena cava to arachidonic acid. It was not observed in thoracic aorta because of the lack of a vasodilatory receptor and/or the poorer ability of this tissue than veins to produce PGE2. Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Arrhythmia Agents; Aorta, Thoracic; Arachidonic Acid; Biphenyl Compounds; Calcimycin; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Endothelium; Epoprostenol; Heptanoic Acids; In Vitro Techniques; Indomethacin; Ionophores; Male; Muscle Contraction; Muscle Relaxation; Prostaglandin Antagonists; Prostaglandin D2; Prostaglandin-Endoperoxide Synthases; Rabbits; Receptors, Prostaglandin; Receptors, Thromboxane; Saphenous Vein; Thromboxanes; Venae Cavae | 1999 |
Neutrophil-induced human bronchial hyperresponsiveness in vitro--pharmacological modulation.
Although it has been postulated that inflammatory cells cause the bronchial hyperresponsiveness which is diagnostic of asthma, until recently there has been little direct evidence of such a link. We have recently shown that calcium ionophore-activated human neutrophils and eosinophils can induce a state of human airway hyperresponsiveness in vitro. In this study we have shown that the anti-inflammatory agent nedocromil sodium, 10(-7) M, inhibited the hyperresponsiveness induced by products released from ionophore activated neutrophils but did not inhibit the release of leukotriene B4 from the same cells. Neutrophil-induced bronchial hyperresponsiveness was also inhibited by pre-treatment of the bronchial tissues with a thromboxane A2 and prostaglandin receptor antagonist, GR32191, 10(-7) M. These findings indicate that cyclooxygenase products are involved in bronchial hyperresponsiveness induced by inflammatory cell products in vitro and that their release can be inhibited by nedocromil sodium. Topics: Biphenyl Compounds; Bronchi; Bronchial Hyperreactivity; Calcimycin; Granulocyte-Macrophage Colony-Stimulating Factor; Heptanoic Acids; Histamine; Humans; Leukotriene B4; N-Formylmethionine Leucyl-Phenylalanine; Nedocromil; Neutrophils; Quinolones; Receptors, Thromboxane | 1993 |